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The objective of this study was to determine the impact of a pharmaceutical care (PC) program in a 
sample of public outpatients with metabolic syndrome (MS) who were being treated in Brazil’s health 
system; the patients were randomized into PC or standard care. The pharmacotherapy follow-up (PF) was 
performed in a total of 120 patients with type 2 diabetes for 6 months. Adherence to treatment (measured 
with the Morisky test), negative outcomes associated with medication (NOM) and anthropometric and 
biochemical parameters were measured before and after PF. The Framingham scoring method was used 
to estimate changes in 10-year coronary heart disease risk scores in all patients. Ninety-six of 120 patients 
had characteristics of MS and were randomized into two groups (G): the control group (CG: 36) and 
the intervention group (IG: 38). Among the MS patients, 100% were taking a glucose-lowering drug; 
many were also taking anti-hypertensive drugs (CG: 72%; IG: 73%), and some patients were also taking 
hypolipemic drugs (CG: 12.0%; IG: 14.7%). Only 20.7% of the IG patients were considered adherent 
to their prescribed drugs. In the CG, an increase of coronary heart disease (CHD) risk (22±2 to 26±3; 
p<0.05) was observed, while in the IG, there was a reduction in CHD risk (22±2 to 14±2%; p<0.01). 
The PC program administered to patients with MS monitored through the primary healthcare services 
of the Brazilian public health system improved patient health, resulting in clinical improvements and a 
decrease in cardiovascular risk in IG patients over a period of ten years.
Uniterms: Pharmaceutical service. Metabolic syndrome/cardiovascular risk. Drug therapy follow-up. 
Medicines/associated negative outcomes.
O objetivo deste estudo foi o de determinar o impacto de um Programa de atenção Farmacêutica (AF) em 
uma amostra de pacientes ambulatoriais de Sistema Público de Saúde do Brasil portadores de Síndrome 
Metabólica, randomizados em AF ou atenção à saúde usual. Realizou-se o seguimento farmacoterapêutico 
com 120 pacientes com diabetes tipo 2 durante seis meses. Avaliou-se o nível de aderência ao tratamento 
(teste Morisky), resultados clínicos negativos associados a medicamentos (RNM), parâmetros bioquímicos 
e antropométricos, antes e após o seguimento. O método de Framingham foi usado para calcular as 
variações no risco de doenças coronarianas em 10 anos em todos os pacientes. Dos 120 pacientes, 96 
tiveram características de SM e foram então randomizados em dois grupos (G): Controle (GC: 36) e 
Intervenção (GI: 38). Entre os pacientes com SM, 100% faziam uso de medicamentos para diminuir a 
glicose, anti-hipertensivos (GC: 72%; GI: 73%) e hipoglicemiantes (GC: 12.0%; GI: 14.7%). Apenas 
20,7% do GI foram considerados aderentes aos fármacos prescritos. No GC foi observado aumento do 
risco de Doença Arterial Coronariana (DAC) (22±2 para 26±3; p<0,05), enquanto no GI foi observado 
redução (22±2 para 14±2%; p<0,01). O Programa de AF para pacientes com SM monitorados na atenção 
primária do Sistema de Saúde Pública brasileiro melhora o funcionamento do serviço resultando na 
melhoria clínica dos pacientes com redução do risco de doença cardiovascular em um período de dez anos.
Unitermos: Atenção farmacêutica. Síndrome metabólica/risco cardiovascular. Seguimento farmacêutico. 
Medicamentos/resultados negativos associados.
C. P. Plaster, D. T. Melo, V. Boldt, K. O. S. Cassaro, F. C. R. Lessa, G. A. P. Boëchat, N. S. Bissoli, T. U. Andrade436
INTRODUCTION
Metabolic syndrome (MS) is a set of interconnected 
risk factors of metabolic origin that may contribute to the 
development of atherosclerotic cardiovascular disease 
(ACD) (Grundy et al., 2005). Additionally, patients af-
fected by MS are 5 times more likely to develop diabetes 
(Lakka et al., 2002).
Metabolic syndrome is characterized by the presence 
of dyslipidemia, glucose intolerance, hypertension and 
excess weight or abdominal obesity, among other abnor-
malities, as defined by the National Cholesterol Education 
Program’s Adult Treatment Panel III (NCEP ATP-III) 
(NCEP, 2002). Consequently, MS triggers a number of 
chronic diseases that require changes in patients’ lifestyles, 
such as weight reduction, increased physical activity and 
non-atherogenic diets, to slow down the progress of the 
disease. However, solely making lifestyle changes may 
be insufficient to reverse all risk factors. In such cases, 
the establishment of a drug regimen is recommended to 
minimize each patient’s clinical events. Because there 
is currently no single drug that can reverse the known 
progression of MS in the long term, it is necessary to treat 
each one of the risk factors separately, thus necessitating 
polypharmacy (Grundy et al., 2005).
Such interventions can often be ineffective because of 
patient noncompliance with treatment, problems related to 
health services, socio-economic issues, adverse reactions to 
treatment and the stage of the disease and associated com-
plications or the presence of co-morbidities (Lessa, 1998).
Adherence is defined as the degree of correlation 
between a patient’s behavior in relation to medical guide-
lines or the advice of health professionals (Lessa, 1998). 
Adherence to treatment is, therefore, a fundamental condi-
tion for the control of non-transmissible chronic diseases 
(Hill, Miller, Degeest, 2011) such as MS.
Consequently, patients with MS may be at risk for 
developing negative outcomes associated with medication 
(NOM), justifying the practice of pharmaceutical care (PC), 
which aims to optimize pharmacological treatment and 
improve the patient’s quality of life (Robinson et al., 2010).
PC practice is expanding worldwide. A systematic 
review examining the effectiveness of PC to improve 
patient outcomes from 1990 to 2003 showed evidence 
that PC services improve medication use and surrogate 
end points such as blood pressure, cholesterol levels and 
glycosylated hemoglobin (Rougheade, Semples, Vitrya, 
2005). There have been several reports on experiences 
with PC programs that addressed patients with hyperten-
sion (Castro et al., 2006; Bhatt, Luqman-Arafath, Guleria, 
2007), diabetes (Horswell et al., 2008; Adepu, Rasheed, 
Nagavi, 2007) and/or dyslipidemia (Tsuyuki et al., 2002; 
Chisholm, Spivey, Mulloy, 2007). A meta-analysis by Ni, 
Chen and Huang (2009) evaluated the association between 
PC and the control of hypertension, demonstrating that PC 
programs could significantly improve blood pressure con-
trol in patients with hypertension. However, a systematic 
review by Aguiar et al. (2012) showed a lack of hardiness 
and many important limitations in the studies concerning 
the use of PC in hypertension. The authors recommended 
improvements in research design and in the demonstration 
of the intervention’s effectiveness. Adepu et al. (2007) 
showed that PC had a positive impact on diabetes treat-
ment by promoting increased patient awareness of the 
disease and changes in dieting and lifestyle, improving 
glycemic control and the patients’ quality of life. Tsuyuki 
et al. (2002), in the Study of Cardiovascular Risk Interven-
tion by Pharmacists (SCRIP), demonstrated that high-risk 
patients who received pharmaceutical intervention showed 
improvement in their cholesterol management.
Experiences with PC have also been reported in Bra-
zil. Castro et al. (2006) observed that a group of patients 
with uncontrolled hypertension accompanied by a program 
of PC showed a trend of greater clinical improvement than 
did the group treated by other professionals but not by a 
pharmacist. Neto et al. (2011) found that a PC program 
in a community health care unit resulted in better clinical 
measurements and reduced cardiovascular risk scores in 
elderly diabetic and hypertensive patients over a 36-month 
period. Correr et al. (2011) demonstrated that a pharmaco-
therapy follow-up of type 2 diabetic patients in community 
pharmacies improved patients’ glycemic control. Our 
group showed that PC improves patient pharmacy service 
satisfaction levels as compared with the satisfaction with 
pharmacies, both private and public, without a PC program 
(Andrade et al., 2009).
However, we did not find any studies that addressed 
the results of a PC program in patients with MS in com-
munity health centers (CHC) in a public health system. 
Therefore, this study aimed to determine the impact of 
a PC program in a sample of public outpatients with MS 
being treated in Brazil’s health system; patients were ran-
domized into PC or standard care. We hypothesized that 
PC would improve the clinical parameters of the patients, 
with a consequent reduction of cardiovascular risk.
METHODOLOGY
Study design of pharmaceutical care program 
evaluation
The primary healthcare of the Brazilian public health 
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system takes place in CHCs, where patients receive free 
health care from professionals in medicine, dentistry, 
nursing, community health and others; pharmacists are 
present in many but not all of these CHCs. Their work 
is not related to healthcare, but simply to purchasing and 
dispensing medicines. The primary healthcare services are 
organized into health programs such as “HiperDia,” which 
is focused on the control and prevention of hypertension 
and diabetes.
This study was a randomized, controlled, longitu-
dinal, prospective clinical trial carried out from October 
2008 to April 2009 in outpatients from a CHC in Vila 
Velha (ES, Brazil). In this CHC, 120 patients were casually 
selected from a population of 174 patients with diabetes 
(type 2) attended by one team of the “HiperDia” program 
(CI=95%; α=0.05). 
In this sample, the presence of MS was evaluated 
according to the criteria of the National Cholesterol Edu-
cation Program (NCEP-ATPIII) (NCEP, 2002) and the 
Brazilian Guidelines for the Diagnostic and Treatment 
of MS (BGMS) (Sociedade Brasileira de Hipertensão, 
2004): abdominal obesity (> 102 cm for men and > 88 
cm for women); hypertriglyceridemia (> 150 mg.dL-1); 
reduced HDL-cholesterol (<40 mg.dL-1 in men and < 50 
mg.dL-1 in women); hypertension (> 130/85 mmHg) and 
fasting glucose (> 110 mg.dL-1). Patients identified with 
MS (n=96) were invited to participate in this study, and 
we performed a case-controlled and randomized study 
with 74 of those patients who agreed to participate. The 
inclusion criterion was that patients had to meet at least 
three of the conditions recommended by the NCEP-ATP 
III and BGMS for the diagnosis of MS.
These patients were randomized into two groups: 
control (n = 36) and intervention (n = 38). The random 
allocation was performed in blocks of six patients each 
and stratified by gender through a computer-generated 
sequence. The control group was typically accompanied 
by members of the CHC team (including physician, nurse, 
nursing assistant, community agents, and others, but not 
a pharmacist) and only initially interviewed by the phar-
maceutical care team to determine socio-economic and 
cultural data, update the pharmacotherapeutic history and 
determine any negative outcomes associated with medica-
tion (NOM).
The intervention group, in addition to receiving 
the initial interview and monitoring by the CHC team, 
participated in the PC program, according to the Dáder 
methodology (Machuca, Fernández-Llimós, Faus, 2003). 
In both groups, NOMs were identified and ranked (Comité 
de Consenso, 2007) when the requirements for the rational 
indication, effectiveness or safety were not satisfactory. In 
the intervention group, pharmaceutical interventions were 
proposed to resolve or prevent the NOMs.
After six months of follow-up, patients from both 
groups had their anthropometric data, laboratory param-
eters and blood pressure measured again. The results of 
the two groups were then analyzed and compared. The 
initial and final measures were taken by pharmacists blind 
to the study.
This study was previously approved by the Institu-
tional Ethics Committee for Research on Humans Beings 
of the University of Vila Velha (protocol number 09/2006).
Evaluation of the mean arterial pressure (MAP), 
anthropometric and laboratory parameters
In this first interview, the presence of MS was deter-
mined by the measurement of blood pressure (BP) using an 
automatic blood pressure unit (HEM-705CPINT, Omron, 
Omron Healthcare, Inc., Illinois, USA). The individuals’ 
pressure levels were rated according to the criteria of 
the VII Joint National Committee (National High Blood 
Pressure Education Program, 2004). A clamp suitable for 
obese patients was used when needed. Anthropometric 
measurements were taken, such as height and weight using 
mechanical isometric balance (Welmy, Sao Paulo - Brazil) 
and abdominal circumference (AC), using an inelastic tape 
positioned in the middle of the distance between the iliac 
crest and the lower costal margin (Sociedade Brasileira 
de Hipertensão, 2007). Biochemical parameters, such 
as fasting glucose, triacylglycerols, HDL-C, low density 
lipoprotein-cholesterol (LDL-C) and total cholesterol, 
were also measured using the enzymatic method (kit 
of reagents: Bioclin, Goiás, Brazil; Spectrophotometer: 
BIOPLUS Bio-200, Bio 200F, SP, Brazil).
The same procedure was carried out after a period of 
six months in both groups, according to the same protocol. 
The collection of these data and laboratory analyses was 
performed by pharmacists who did not participate in the 
monitoring of the patients and were therefore not aware 
to which group the patients belonged.
Socio-economic-cultural and 
pharmacotherapeutic history data collection
A structured questionnaire, divided into three sec-
tions, was applied in the first meeting with patients from 
both groups. In the first section, socio-economic infor-
mation was collected, including age, gender and family 
income. In the second section, patients’ knowledge of MS 
and their family histories of diabetes and cardiovascular 
disease were addressed; information was also collected on 
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eating habits, practice of physical activity, consumption of 
alcohol, smoking and the presence of prior cardiovascular 
co-morbidities. In the third section, patients’ pharmaco-
therapeutic data were collected, with a focus on medicines 
used for the control of clinical events related to the MS.
Monitoring of patients in the control group
After the first interview, patients in the control group 
had no more pharmaceutical interventions except to con-
firm with the CHC team that the patients were adhering 
to the “Hiperdia” program, including attending all the 
consultations and/or participating in all the interventions 
recommended by the program during the study period. The 
exclusion criterion for patients in the control group was 
lack of adherence to this healthcare program. According 
to this criterion, seven patients were excluded, and their 
initial data are not part of the results of this work.
Monitoring of patients in the intervention group - 
pharmaceutical care program
The patients in the intervention group, in addition to 
participating in the initial interview, were accompanied by 
the PC program in accordance with the Dáder methodol-
ogy (Machuca, Fernández-Llimós, Faus, 2003), which was 
adapted to the reality of outpatient CHC care. The care 
protocols and monitoring instruments used were based 
on protocols and tools that had been previously validated 
(Baena et al., 2001). Information, such as primary health 
complaint, symptoms and the presence of allergic reac-
tions, was collected. Data on medicine, dosage, route of 
administration and frequency of use were also evaluated.
The Third Consensus of Granada (Comité de Con-
senso, 2007) proposed and adopted the following defini-
tion of “negative outcomes associated with medication”: 
“patient health outcomes that are not consistent with the 
objectives of pharmacotherapy and are associated with 
the use or errors in the use of medicines.” A NOM was di-
agnosed when rational indication, effectiveness, or safety 
requirements were not satisfied. The most likely reasons 
and possible solutions for the occurrence of NOM were 
discussed with the patient by the pharmacist. In more 
complex situations, the pharmacist discussed the problem 
with the consulting physician; this strategy is part of the 
Dáder method, and because some problems could have 
serious consequences, it was applied to the control group 
as well (Castro et al., 2006).
Performing an analysis related to medicine usage, 
NOMs were identified according to the Third Consensus 
of Granada (Comité de Consenso, 2007). The NOMs were 
classified into three groups: necessity, effectiveness and 
safety.
The follow-up program in the intervention group 
occurred over six months, with a monthly pharmaceuti-
cal interview and more frequent contact by phone when 
necessary. The pattern of therapeutic goals to be reached, 
medicine indication and dosage regimen of the NECP-
ATP III (NCEP, 2002) and BGMS (Sociedade Brasileira 
de Hipertensão, 2004) were used to evaluate whether 
the patients’ clinical conditions were under control and 
whether the proper pharmacotherapeutic standards were 
being used. In this way, the necessity, effectiveness and 
safety of the pharmacological treatment were identified 
and the NOMs were determined. 
Treatment evaluation was performed in each in-
person meeting by BP and anthropometric measurement 
(as described earlier in this study) and by the capillary 
determination of the fasting glucose, triglycerides and 
cholesterol (Accutrend GCT monitor, Roche, São Paulo, 
SP, Brazil; reagent tests tips: Accutrend Glucose, Tri-
glycerides, Cholesterol, Roche, São Paulo, SP, Brazil). 
Meetings were scheduled at least 24 h in advance. Patients 
who did not attend six PC interviews and all meetings of 
the “Hiperdia” program were considered non-adherent to 
the PC program and were excluded from the study. Four 
subjects attended fewer than six meetings, and their data 
were not used in this work. 
The pharmaceutical interventions were grouped into 
three broad categories: a) lifestyle; b) correct use of the 
medicines and c) pharmacist-doctor interaction. Interven-
tions were oral, written or both, and educative instructional 
material about lifestyle modifications was distributed. The 
interventions with the physicians were conducted orally, 
by letter, or both. 
The primary reasons and possible solutions for the 
NOMs identified were discussed with the patients by 
the PC team; in more complex cases where the doctor’s 
intervention was required, the clinical team was notified. 
NOMs were only considered resolved when the 
negative clinical results found reverted to standard values 
(Pan-American Health Organization, 2007). A potential 
NOM was considered prevented when it did not manifest 
during the follow-up period and when a pharmaceutical 
intervention was performed to prevent it.
Evaluation of adherence levels to the 
pharmacological treatment – The Morisky test
The Morisky test (Morisky, Green, Levine, 1986) 
was applied to help evaluate patient adherence levels to 
pharmacological treatment. According to this test, patients 
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are considered adherent (high adherence level) when their 
answers to all four test questions are negative. When any 
one of the questions is answered positively, the patient is 
considered non-adherent (low adherence level). It is also 
possible to characterize whether the low level of adherence 
is intentional or non-intentional (Table I).
Cardiovascular risk evaluation
To evaluate cardiovascular risk, the revised Fram-
ingham criteria (Wilson et al., 1998) were applied to both 
control and intervention groups at the beginning and the 
end of the study period. According to the Framingham 
score, a patient’s risk for developing cardiovascular dis-
ease (CVD) in ten years is calculated by the sum of the 
points assigned for the following variables: age, gender, 
plasmatic LDL-cholesterol, HDL-cholesterol, blood 
pressure, presence of diabetes and smoking (Wilson et 
al., 1998).
Statistical analysis
Statistical analysis was carried out using SPSS 
for Windows, version 13.0 (SPSS Inc., Chicago, USA). 
Simple relative frequencies were performed with the 
qualitative variables in each group and were also com-
pared between the two groups (cross frequencies). The 
Chi-square test was applied to the significance level of 
5%. Descriptive statistics were applied to the quantitative 
variables, and the differences were determined using paral-
lel (within the same group) and non-parallel (between the 
groups) Student t tests for a confidence interval of 95%. 
These data were expressed as the mean ± standard error 
of the mean (SEM).
RESULTS
Initial profile of the patients in the Control and 
Intervention groups
A high frequency of MS (80%) was identified in dia-
betic outpatients from the CHC in Vila Velha (ES, Brazil). 
This result was unsurprising because diabetes was present 
in all patients and only two additional criteria from NECP-
ATP-III (NCEP, 2002) or BGMS (Sociedade Brasileira 
de Hipertensão, 2004) were necessary for a diagnosis of 
MS. As such, 96 of 120 patients were identified with MS.
Table II shows data related to the age, gender, family 
income, lifestyle and cardiovascular disease family history 
of the patients in the control and intervention groups. In 
both groups, the subjects were primarily underprivileged 
(receiving approximately 1 – 2 times the Brazilian mini-
mum salary, i.e., US$ 250.00 monthly), female and elderly. 
There were no significant differences among the variables 
between the two groups (P>0.05).
The initial values of systolic (SAP) and diastolic 
arterial pressure (DAP), anthropometric measures and 
biochemistry parameters of both groups are shown in Table 
III. Statistical analysis indicated that the groups were well 
matched (P>0.05 in all cases).
In terms of the number of medications in use by both 
groups, all patients were taking at least one medicine. Anti-
diabetic drugs were the primary type of medication in use 
(100% of patients in both groups were taking anti-diabetic 
drugs), followed by anti-hypertensive drugs (72.0%; n=21 
in the Control group and 73.5%; n=25 in the Intervention 
group). Hypolipemic drugs were less frequently used 
(12.0%; n=4 in the Control group and 14.7%; n=5 in the 
Intervention group). The most frequent number of medica-
tions in use was three to four (52% and 50% for control 
and intervention groups, respectively), followed by one to 
two medicines (28% and 29.4% for control and interven-
tion groups, respectively) and then five or more (21% and 
22% for control and intervention groups, respectively). 
The frequencies were not statically different between the 
groups studied (P>0.05).
One hundred thirty-two and 129 NOMs were iden-
tified in the Control and Intervention groups, respectively 
(P>0.05). The primary NOMs were those related to ef-
ficiency (Control=48.5%, n=64; Intervention=47.3%, 
n=61; P>0.05), followed by safety (Control=35.2%, 
n=45; Intervention=36.4%, n=47; P>0.05) and neces-
sity (Control=17.4%, n=23; Intervention=16.3%, n=21; 
P>0.05). 
TABLE I - Questions on the Morisky test and the adherence level classification indicated by positive answers to the questions
Morisky test Questions Non-intentional Intentional
“Do you sometimes forget to take your medicine?” X
“Are you sometimes careless about taking your medicine at the scheduled time?” X
“When you feel good, do you sometimes stop taking your medicine?” X
“When the medicine makes you feel bad, do you sometimes stop taking it?” X
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TABLE II – Socio-economic, lifestyle and cardiovascular disease family history of patients from the Control and Intervention groups
 Intervention Control
% n % n
AGE (YEARS)
30-39 2.9 1 0 0
40-59 44.1 15 36.0 10
60 or older 52.9 18 64.0 19
GENDER
Male 29.4 10 40.0 12
Female 70.6 24 60.0 17
FAMILY INCOME (Brazilian minimum wage*)
1-2 64.7 22 72.0 21
3-4 29.4 10 24.0 7
≥ 5 5.9 2 4.0 1
DO YOU PRACTICE PHYSICAL ACTIVITY?
Yes 38.2 13 40.0 12
No 61.8 21 60.0 17
ARE YOU ON A DIET?
Yes 82.4 28 84.0 24
No 17.6 6 16.0 5
IS THERE ANY HISTORY OF CARDIOVASCULAR DISEASE IN YOUR FAMILY?
Yes 70.6 24 72.0 21
No 29.4 10 28.0 8
* Brazilian minimum wage in 2012 corresponds to US$ 245.00










SAP (mm Hg) 138±3 138±4 141±4 131±3ae
DAP (mm Hg) 80±1 80±2 81±3 78±2
SAPH (mm Hg) 146±2 149±4 147±5 133±4ace
DAPH (mm Hg) 81±2 85±3 81±3 78±2bdf
Body weight (Kg) 80±4 79±3 81±4 78±4
Men WC (cm) 102±3 106±4 103±4 105±4
Women WC (cm) 104±3 102±2 105±4 94±2ace
Plasma glucose (mg.dL-1) 181±14 198±15 173±13 130±12bdf
Total cholesterol (mg.dL-1) 209±7 205±9 210±4 182±5bdf
Triglycerides (mg.dL-1) 207±20 186±15 174±14 165±13
Men HDL-c (mg.dL-1) 44±3 40±3 40±3 47±2ace
Women HDL-c (mg.dL-1) 45±3 42±2 41±3 49±1ce
LDL (mg.dL-1) 140±6 146±6 132±4 111±5bdf
SAP: systolic arterial pressure; DAP: diastolic arterial pressure; SAPH: SAP of hypertensive patients; DAPH: DAP of hypertensive 
patients; WC: waist circumference. Values are expressed as the mean ± SEM. ap<0.05 and bp<0.01 compared with initial control 
group data; cp<0.05 and dp<0.01 compared with the initial intervention data; ep<0.05 and fp<0.01 compared with the final control 
group data.
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Analysis of the parameters in the intervention 
group
The pharmaceutical team performed a set of inter-
ventions that resulted in the resolution or improvement 
of the NOMs. A NOM was considered resolved when 
parameters evaluated reached the standard values. A NOM 
was considered only ameliorated when parameters did not 
reach the standard values but were better than they had 
been at the beginning of the follow-up program. The fre-
quency of resolution or improvement of the NOMs related 
to necessity found were 82% for improvement and 49% 
for resolution. With NOMs related to efficiency, the results 
showed improvement in 90% of cases and resolution in 
54%. With NOMs related to safety, the results showed 
100% improvement and 83% resolution.
The number of medicines in use by the patients from 
the Intervention group was unchanged during the follow-
up program (3.6±0.3 vs. 3.7±0.3 at the beginning and the 
end, respectively).
It was observed that 50% of the patients (n=17) 
in the Intervention group reported symptoms that were 
compatible with adverse drug reactions (ADR) to the 
drugs in use. These patients reported 29 ADRs; of these, 
gastrointestinal problems (34.5%; n=10), manifested 
hypoglycemia (24.1%; n=7), leg pain (13.9%; n=4) and 
cough (7.0%; n=2) were the most frequent. Headache, 
weight gain, hyperglycemia, dizziness, cramp and asthenia 
were reported once (3.4%; n=1).
Adherence to treatment was evaluated in the inter-
vention group using the Morisky test (Morisky, Green, 
Levine, 1986). Only 20.7% (n=7) participants were con-
sidered adherent to treatment based on the Morisky scale, 
and 55.9% (n=19) were classified as non-intentional non-
adherent subjects; 23.5% (n=8) presented both intentional 
and non-intentional non-adherence tendencies. 
Comparison of clinical and laboratory data 
between the Control and Intervention groups 
after six months of follow-up
Table III shows that nearly all clinical parameters 
evaluated were improved at the end of the study in the In-
tervention group when compared with their initial values. 
The same result was observed when the final data of 
this group were compared with the final data of the Con-
trol group. On the other hand, the final data of the Control 
group were not different from the data at the beginning 
of the study. Although there was no significant difference 
between the SAP and DAP of the Intervention group when 
compared with their initial data, when these parameters 
were analyzed only in patients with hypertension, BP 
values were improved in hypertensive patients in the 
Intervention group and unchanged in those in the Control 
group. When the delta of BP of hypertensive patients was 
calculated, a higher reduction in SAP (Control = +5±4 mm 
Hg vs. Intervention = -13 ± 3 mm Hg; p<0.05) and DAP 
(Control = +1±4 mm Hg vs. Intervention = - 8±3 mm Hg; 
p<0.05) was observed in the patients in the Intervention 
group. 
The observed findings were the same for body 
weight: although the final values did not differ from the 
initial ones in both groups, the delta of body weight was 
higher in the Control than in the Intervention group (Con-
trol = +1±1 Kg vs. Intervention = -2.6±1 Kg; p<0.05), 
which indicates a greater weight reduction in patients who 
received pharmacist follow-up. 
Table IV compares the frequency of improvement 
or worsening of blood pressure and anthropometric and 
biochemical measures in the patients in the intervention 
group with those in the control group.
Assessment of global cardiovascular risk of 
patients
Figure 1 shows the degree of cardiovascular risk 
in Control and Intervention patients before and after the 
six-month study. Increased coronary heart disease (CHD) 
risk (22±2% to 26±3 p<0.05) was observed in the Control 
group, whereas the intervention group showed a reduction 
in CHD risk (22±2 to 14±2%; p<0.01). 
DISCUSSION
The primary contribution of this study was to dem-
onstrate that patients with MS who were monitored by a 
public health system had better clinical results, improved 
health conditions and reduced cardiovascular risks when 
their care was accompanied by PC service over 6 months, 
while the same improvements were not observed among 
the patients who did not receive pharmaceutical interven-
tion.
The effectiveness of pharmacist-physician collabo-
ration is consistent with previous published investigations 
of the role of pharmacists in the treatment of dyslipidemia, 
diabetes, hypertension (Ramser et al., 2008; Carter et 
al., 2009; Kelly, Booth, 2008; McLean et al., 2008) and 
metabolic syndrome (Hammad et al., 2011). Similarly, our 
results are also consistent with others studies performed in 
Brazil on the control of hypertension (Castro et al., 2006), 
diabetes (Correr et al., 2011) or hypertension and diabetes 
(Neto et al., 2011).
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When a NOM was found in the patients from the 
Intervention group, it was analyzed, and the best possible 
intervention was used to resolve it. The NOMs most fre-
quently identified were related to the effectiveness of the 
therapy. All patients were taking medication to control 
diabetes; however, 91.2% of them had glucose levels 
greater than 110 mg/dL. Similarly, 73.5% of patients took 
medicine to control hypertension, but it was still uncon-
trolled in 56% of these patients. These results indirectly 
indicate a low level of pharmacotherapy adherence, which 
was confirmed by the Morisky test scores.
Based on the Morisky test, the majority of patients 
had low behavioral adherence levels, which were most 
frequently non-intentional. This finding implies that pa-
tients, through forgetfulness or neglect, do not use their 
medicaments correctly. Forgetfulness was reported by 
Sewitch et al. (2003) as the primary feature responsible 
for low adherence.
FIGURE 1 - Reduction of cardiovascular risk evaluated through 
the Framingham score. A: basal values before the interventions; 
B: values calculated after six month of control or intervention 
follow-up. Values are expressed as the mean ± S.E.M. *p<0.05 
and **p<0.01 compared with initial Control values; ##p<0.01 
compared with initial Intervention values; §§p<0.01 compared 
with final Control values.




 Control 36.0% 64.0% -
 Intervention 90.9% 9% -
Weight
 Control 27.3% 72.7% -
 Intervention 85.3% 14.7% -
Systolic blood pressures
 Control 36.0% 32.0% 32.0%
 Intervention 56.2% 21.9% 21.9%
Diastolic blood pressures
 Control 28.0% 40.0% 32.0%
 Intervention 53.1% 37.5% 9.4%
Glucose
 Control 44.0% 56.0% -
 Intervention 91.2% 8.8% -
Total Cholesterol
 Control 32.0% 60.0% 8.0%
 Intervention 79.0% 18.0% 2.9%
Triglycerides
 Control 40.0% 60.0% 0%
 Intervention 67.7% 29.4% 2.9%
c-HDL
 Control 33.3% 66.7% 0%
 Intervention 82.1% 14.3% 3.6%
c-LDL
 Control 29.4% 70.6% 0%
 Intervention 92.8% 3.6% 3.6%
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Therefore, the PC program promoted the correct 
use of the medicines to improve the effectiveness of the 
prescribed treatments. There was intervention to clarify 
how to correctly take the medication and emphasize the 
importance of correctly following the prescription and 
remembering to take the medication; in addition, interven-
tions were made in collaboration with the clinical staff to 
adjust dosage or change medications when necessary. Al-
though changes in adherence levels to treatment were not 
directly evaluated, changes were indirectly demonstrated 
by the clinical results. 
Another pharmaceutical action was the use of oral 
and written counseling and educative material to help the 
patients make and adhere to improved lifestyle changes. 
The patients were given advice about which foods should 
be avoided and about exercise; for instance, at least 30 
minutes five days a week of light-to-moderate physical 
activity was recommended for achieving beneficial effects 
on cardiovascular disease and other chronic diseases such 
as DM (Clifford et al., 2005), dyslipidemia, and high arte-
rial blood pressure (Sociedade Brasileira de Hipertensão, 
2004). 
Studies have demonstrated that PC has a posi-
tive effect on the control of dyslipidemia (Tsuyuki et 
al., 2002), glycemia (Adepu, Rasheed, Nagavi, 2007; 
Clifford et al., 2005; Nau, Pacholski, 2007) and blood 
pressure (Castro et al., 2006; Clifford et al., 2005; Nau, 
Pacholski, 2007). Tsuyuki et al. (2002) demonstrated 
that pharmaceutical interventions improved the process 
of controlling cholesterol in high-risk patients, and Cas-
tro et al. (2006) demonstrated a tendency toward better 
blood pressure control in resistant hypertensive patients 
who participated in a PC program (Castro et al., 2006). 
Lindenmeyer et al. (2006) noted whether the interven-
tion made by pharmacists (in approximately 21 stud-
ies) in the care of diabetics had improved adherence to 
medication treatment, which indicated potential benefits 
specifically from better educating patients (Lindenmeyer 
et al., 2006). These results support our findings that 82% 
of NOMs related to necessity were at least resolved, 
which implies the improvement and/or adequacy of the 
reference values of the majority of patients in their an-
thropometric parameters and lipid profiles.
The primary difficulty with necessity-related 
NOMs was that patients did not use their necessary 
medications. This finding may be explained by the fact 
that most patients had dislypidemia, but 85.3% of them 
did not use medicaments to control it, even though they 
met the inclusion criteria of the Clinical Protocol and 
Therapeutic Guideline for the treatment of dislipidemia 
(Brasil, 2002). Although the latest State Relation of 
Essential Medicaments and Exceptional Medicaments 
(Espírito Santo, 2007) included synvastatin in the group 
of essential medicaments, during the course of this study, 
the hypolipemics were considered exceptional and were 
not widely available in CHCs. Therefore, the Brazilian 
public health system’s limited access to primary health-
care for low-income patients, which prevents them from 
purchasing these medicaments, explains the frequency 
of necessity-related NOMs.
NOMs of safety were also frequent, which is 
usually associated with the onset of an ADR. The fact 
that most patients in this study were elderly could help 
explain the high levels of this ADR; elderly patients are 
more susceptible to adverse reactions during treatment 
with anti-hypertensive drugs (Benson, Vance-Bryan, 
Raddatz, 2000). The most frequently reported ADR was 
gastrointestinal discomfort. A probable explanation for 
this finding is the fact that most patients use metformin, 
a medicament capable of causing gastrointestinal events 
(ADA, 2000). Many patients took their metformin before 
meals, which promotes gastrointestinal discomfort; these 
individuals were instructed to take it immediately after 
meals. With this medicine and others that are known to 
cause gastrointestinal discomfort, it was recommended 
that patients take them with plenty of water.
Metabolic syndrome (MS) is a complex disorder 
consisting of a constellation of risk factors for cardio-
vascular disease and is responsible for an estimated 2.5 
times greater risk of cardiovascular mortality (Socie-
dade Brasileira de Hipertensão, 2004). Therefore, it is 
extremely important to delay the progression of MS by 
controlling the risk factors. Most NOMs were resolved 
or improved, and this result was sufficient to show better 
clinical profiles in the patients in the Intervention group 
compared with those in the Control group. The outcomes 
of the 10-year CHD risk predictions using Framingham 
scores showed a clear positive impact of our interven-
tion on reducing the risk of CHD in Intervention group 
patients.
Additionally, Grymonpre et al. (1994) reinforce the 
idea that the pharmacist’s intervention increases elderly 
patients’ adherence to their therapeutic regimens, and 
pharmacist´s intervention may also promote the reduction 
of hospital costs by reducing the number of prescriptions, 
hospitalizations and medications associated with ADR. 
Thus, as part of the multidisciplinary team providing 
pharmaceutical care, the pharmacist may improve patients’ 
clinical status through pharmacotherapy follow-up, assist-
ing with effective therapy and the prevention, detection 
and resolution of NOMs and helping to improve patient 
quality of life (Strand et al., 2004). 
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CONCLUSION
The present study demonstrates that a PC program 
used with patients with MS monitored at a primary 
healthcare center of the Brazilian public health system 
improves patient health and functioning; there was sig-
nificant improvement in the Intervention group, and this 
improvement was greater than that found in the Control 
group. In the intervention group, identified NOMs were 
mostly resolved, improved or prevented by pharmaceuti-
cal interventions, which resulted in clinical improvements 
superior to those found in the Control patients, including 
a decrease in the predicted ten-year risk of developing 
cardiovascular disease.
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